| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
|---|
| Outline of Final Research Achievements |
Osteoclasts are multinucleated giant cells specialized in bone resorption, and are the major therapeutic target in diseases such as Osteoporosis and metastatic bone tumor. Receptor activator of NF-κB (RANK) is a member of the tumor necrosis factor receptor (TNFR) family expressed in osteoclast precursors, and RANK-RANK ligand (RANKL) signaling is a key system for differentiation, during differentiation of bone marrow mono-nucleated cells into osteoclast precursors. We had cloned a 6-kb fragment containing the 5’-flanking region of the RANK gene and have analyzed the binding elements of transcription factors. RANK transcription was positively regulated by c-fos/AP-1. We have identified splicing variant of mouse and human RANK gene (vRANK) that contains an intervening exon between exons 1 and 2 of full-length RANK (fRANK) mRNA. Since this novel exon contains a stop codon, vRANK encodes short truncated amino acids. We have started to generate a vRANK-overexpressed transgenic mouse.
|
